I can give one specific and recent example of a biotech company that uplisted to the Nasdaq. Stellar Biotechnologies effected a 10:1 reverse split in September of 2015 and uplisted to the Naz on Nov. 5th....about 4 months ago.

On the day the stock first traded on the Naz the Canadian shares of KLH hit a high of $12.35, the PPS they also closed at. A couple days later they hit $13, and then the slide began....they're now trading under $8.

I agree with the sentiment that a Naz listing would increase our exposure...but in of itself I don't think it would be enough to lift the share price. We saw some pretty incredible price appreciation around this time last year while still listed OTC stateside..